Advocacy Wealth Management LLC Grows Holdings in Stryker Corporation $SYK

Advocacy Wealth Management LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 24.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 48,645 shares of the medical technology company's stock after acquiring an additional 9,551 shares during the period. Advocacy Wealth Management LLC's holdings in Stryker were worth $15,315,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Varma Mutual Pension Insurance Co raised its position in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock worth $18,842,000 after buying an additional 5,100 shares during the period. QRG Capital Management Inc. boosted its holdings in Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock worth $21,281,000 after acquiring an additional 4,186 shares during the period. Rakuten Investment Management Inc. acquired a new stake in Stryker during the 2nd quarter valued at $18,646,000. Swedbank AB grew its stake in shares of Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock valued at $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its holdings in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock worth $9,426,000 after purchasing an additional 6,367 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

SYK opened at $331.32 on Monday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a PEG ratio of 2.11 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average of $329.10 and a 200-day moving average of $331.29.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 EPS. The firm's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's payout ratio is currently 36.48%.

Analysts Set New Price Targets

Several research firms recently issued reports on SYK. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Citizens Jmp reduced their price objective on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. JPMorgan Chase & Co. decreased their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. BMO Capital Markets started coverage on Stryker in a research report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price target on the stock. Finally, Truist Financial lifted their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company's stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the firm's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source